CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversity of Minnesota
About this trial
The purpose of this study is to study how CMVIG interacts with the body and to see if it might work to prevent kidney transplant patients from becoming infected with CMV.
Eligibility criteria
Qualifiers
Adult (18-70 year old) kidney transplant recipients
Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion
CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor
EBV IgG Positive
Disqualifiers
Pregnant people
Subjects unwilling to sign consent and complete follow up visits
Subjects with IgA immunodeficiency
Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment
Trial design
Treatments tested in this trial
- Cytogam
Treatment groups
30 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov